Drug profile · INN
prucalopride succinate
PRUCALOPRIDE SUCCINATE
prucalopride succinate (PRUCALOPRIDE SUCCINATE) is a serotonin 4 (5-ht4) receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — prucalopride succinate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
prucalopride succinate (PRUCALOPRIDE SUCCINATE) is a serotonin 4 (5-ht4) receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 4 (5-HT4) receptor agonist
Primary target: 5-hydroxytryptamine receptor 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is prucalopride succinate?
prucalopride succinate (PRUCALOPRIDE SUCCINATE) is a serotonin 4 (5-ht4) receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for prucalopride succinate?
PRUCALOPRIDE SUCCINATE is a marketed brand name for prucalopride succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of prucalopride succinate?
prucalopride succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.